Innovaderm recognized by pharma and biotech sponsors as top performer champion, sweeping all categories of the 2023 CRO Leadership Awards
1.5.2023 16:00:00 EEST | Business Wire | Press release
Innovaderm has been honored as a Champion of the 2023 CRO Leadership Awards, garnering top performer accolades across all core categories of Expertise, Capabilities, Quality, Reliability and Compatibility. By scoring as a top performer, in relation to the weighted average of other CROs included in ISR’s annual CRO Quality Benchmarking survey, Innovaderm has been awarded the additional designation of Champion.
Innovaderm is the leading dermatology CRO, built upon deep dermatology expertise and over 20 years of success, offering full-service capabilities across all phases of clinical trials, towards the goal of improving patient’s lives.
“CRO selection is one of the most important and strategic decision study sponsors must make for their clinical research programs. Winning organizations are selected in each of these categories based on the market research our colleagues at ISR Reports conducted with decision makers at study sponsor companies over the last 18 months. Congratulations to all the winners for your outstanding performance and vital contribution to the clinical research industry.” Amit Dua, Vice President, Market Development, Clinical Leader.
“We are very pleased to have been awarded this prestigious recognition for the third year in a row, by our clients and collaborators,” Dr. Robert Bissonnette, Founder and CEO of Innovaderm, commented. “It is a tremendous honor to see our work acknowledged by biotech and pharma sponsors. At Innovaderm, we pride ourselves on the excellence in the execution and delivery of high-quality services, in the interest of advancing scientific and medical research.”
To learn about Innovaderm’s services, visit our website.
Innovaderm Research Inc.
Innovaderm Research Inc. is the leading full-service dermatology CRO. Founded in 2000, Innovaderm’s deep expertise and experience enables the ability to operationalize all aspects of clinical research, and deliver excellence across early to late phase studies. Innovaderm’s mission is to drive innovative research initiatives towards the goal of improving patients’ lives.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005001/en/
Contact information
Mikael Leclaire
Marketing Coordinator
busdev@innovaderm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights24.3.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlights. “COMP360 is shaping the future of mental healthcare, and we are moving the field of psychiatric medicine forward for the millions of people urgently needing better options. As the potential first classic psychedelic approved by the FDA, COMP360 is redefining rapidity and durability with response as early as the day after dosing and lasting through at least 6 months with just one or two doses – an unmatched clinical profile and important advancement for those living with TRD,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “We look forward to our upcoming FDA meeting to confirm our NDA submission strategy, and we continue to advance our commercial readiness to be launch-ready by the end of this year. We are also initiating our late
Carta Launches Unified Fund of Funds Solution to Automate LP Workflows and Portfolio Visibility24.3.2026 12:01:00 EET | Press release
Carta, the world’s first fully interconnected system for private capital, today announced its solution for Fund of Funds, a new offering designed to help managers automate LP reporting, eliminate manual document processing, and gain clearer visibility into their underlying portfolio exposure. The product expands a critical link in Carta’s ERP for private capital, bringing LP investment data, fund accounting, and portfolio analytics onto a single platform, while more deeply connecting allocators with the GP ecosystem. Fund of Funds represents a critical and growing segment of the private capital ecosystem, projected to reach $450 billion by 2033 as investors seek diversified exposure to private markets. Yet, operating a fund of funds remains highly complex. Managers sit at a unique intersection of the ecosystem, investing as LPs across multiple funds while also serving as GPs to their own investors. As a result, teams are forced to navigate dozens or more of LP portals, manually process
Meeting Rising AI Expectations and Removing Friction Key to Meeting Needs of B2B Buyers Across Europe24.3.2026 12:00:00 EET | Press release
According to a new European study1 of 550 business buyers commissioned by TreviPay, the global B2B payments invoicing and payments network, friction in the B2B buying process in the form of slow onboarding and inconsistent invoicing along with rising expectations for AI-enabled processes are where businesses are experiencing threats to loyalty beyond price. “Across Europe and the UK, finance teams are navigating economic pressure, regulatory complexity and rising buyer expectations,” said Inez Berkhof-Hollander, TreviPay’s Vice President of EMEA. “Our research shows payment and invoicing experiences now play a decisive role in supplier selection.” Top Three European Market Expectations in 2026 1. More AI-driven purchasing options vary by country Nearly 8 in 10 business buyers always or often use AI technologies in B2B purchasing and payment processes; a significant shift from previous years. AI is seen primarily as a means to improve decision-making through data insights (20%), strengt
OCTO and Volkswagen Group Info Services AG Form Partnership for Fleet Data Integration24.3.2026 11:00:00 EET | Press release
OCTO, a leading company in the field of telematics, data analytics and AI-driven solutions for insurance and fleet management, announces a strategic partnership with Volkswagen Group Info Services AG. The goal of this cooperation is to expand data solutions for fleet operators by directly integrating vehicle data from the brands Volkswagen Passenger Cars, Volkswagen Commercial Vehicles, Škoda, Seat, Cupra and Audi. Through this partnership, OCTO gains direct access to vehicle data from fleet vehicles of these six Volkswagen brands. This enables innovative mobility services for fleet managers, including maintenance management, theft protection, damage management, fraud detection, driving behavior analysis, activity reports, e-mobility management, corporate car sharing, and many other functions. These services utilize data such as mileage, fuel consumption, EV status, warning messages, and other parameters, without requiring additional hardware installations. Innovation Through Data Inte
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 10:30:00 EET | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. About ASTX295 ASTX295 is a potent, highly selective, potentially best-in-class MDM2 antagonist that has completed a phase I study (NCT03975387) in over 100 patients with advanced solid tumors. Rationally designed to exhibit a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom